The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who ...

Citation: Semaglutide's cardiovascular benefits are maintained in people with impaired kidney function, research finds (2024, September 11) retrieved 16 May 2025 from https://medicalxpress.com ...

Semaglutide, a glucagon-like peptide 1 analogue, reduces the rate of cardiovascular events in patients with type 2 diabetes mellitus who are at high cardiovascular risk. These findings from the ...

Semaglutide’s cardiovascular benefits remain effective in individuals with impaired kidney function, offering heart protection even with reduced renal health. About Careers Internship MedBlog ...

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss. The analysis comes from long-term ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

In participants with impaired kidney function (eGFR <60) semaglutide was linked to a 31% reduction in MACE (9.7% semaglutide vs. 13.5% placebo), and a 33% lower risk of MACE or death from any cause.

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

The researchers looked at data from 4,286 people -- out of a total of 17,605 from the landmark Semaglutide and Cardiovascular Outcomes (SELECT) trial who were randomly assigned either semaglutide ...

Among patients who have obesity-related heart failure with preserved ejection fraction (HFpEF), once-weekly semaglutide 2.4 mg (Wegovy; Novo Nordisk) induces greater weight loss in women than in men ...

In the longest clinical trial yet of semaglutide, a prescription drug sold under the brand names Wegovy and Ozempic, researchers analyzed the drug's long-term weight loss effects. Published in Nature ...